| |
Pharmaceutical Growth in an Economic Downturn:
Wrap-up for 2008, Outlook for 2009
In 2008, the pharmaceutical industry proved to be one of the few resilient businesses in the face of recession. The effects of the credit crunch did not stop a series of acquisitions, including Daiichi Sankyo purchasing the first pure play generics firm, Ranbaxy. In fact, over 50 mergers and acquisitions (M&As) were reported in the pharmaceutical industry in 2008 alone.
IHS Global Insight's report, Pharmaceutical Growth in an Economic Downturn: Wrap-up for 2008, Outlook for 2009, explores the key developments in 2008 and provides an outlook for 2009.
The report addresses the following key questions:
- How did all the M&As affect the pharmaceutical industry overall?
- What policy changes were implemented in 2008 that shaped the strategies of major pharmaceutical firms, including Pfizer, Merck & Co., and GlaxoSmithKline? What sort of strategies are these companies looking to implement?
- What patent expiries are coming up? What sort of product approvals, litigation settlements, and intellectual property related to events influencing market dynamics should we expect in 2009?
- What challenges will drug firms face in 2009? How much of a challenge will cost containment, increase in generic competition, and sustained pressure on drug pricing and reimbursement prove to be?
- What were the defining events of 2008 for emerging and developed markets, and what can we expect in 2009?
For more information, contact:
North America:
Michael D'Aleo
E-mail: michael.daleo@ihsglobalinsight.com
Tel: +1 781 301 9159
Europe, Middle East, and Africa:
Sedinam Nartey
E-mail: sedinam.nartey@ihsglobalinsight.com
Tel: +44 20 7452 5102
Asia:
Reno Sio
E-mail: reno.sio@ihsglobalinsight.com
Tel: +65 6430 6621
|
|
|
